Merus Labs International Inc. (TSE:MSL – Free Report) (NASDAQ:MSLI) – Analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Merus Labs International in a report released on Friday, August 22nd. HC Wainwright analyst A. He anticipates that the specialty pharmaceutical company will post earnings per share of ($0.06) for the quarter. HC Wainwright also issued estimates for Merus Labs International’s Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.06) EPS and Q4 2026 earnings at ($0.06) EPS.
Merus Labs International Stock Performance
Merus Labs International has a 1 year low of C$0.95 and a 1 year high of C$1.76.
About Merus Labs International
Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin.
Further Reading
- Five stocks we like better than Merus Labs International
- What is a Bond Market Holiday? How to Invest and Trade
- Costco and Ross: 2 Ways to Play the Consumer Divide
- How to Effectively Use the MarketBeat Ratings Screener
- Is Paramount Skydance a Buy Post-Merger, Short Squeeze?
- Bank Stocks – Best Bank Stocks to Invest In
- V2X Stock: Defense Underdog Riding a $4.3B Air Force Contract
Receive News & Ratings for Merus Labs International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International and related companies with MarketBeat.com's FREE daily email newsletter.
